Nicolas Lebrun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicolas Lebrun has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Ramoz
Universite Paris Cite
3 shared publications - Chloé Tezenas du Montcel
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Team “Vulnerability to Psychiatric and Addictive Disorders”, Paris, France
2 shared publications Philibert Duriez
Université de Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM UMR1266, « Genetic vulnerability to addictive and psychiatric disorders » team, Paris, France
2 shared publications- Philip Gorwood
Universite Paris Cite
2 shared publications - Virginie Tolle
Institute of Psychiatry and Neuroscience of Paris (IPNP), Université Paris Cité, INSERM U1266, Paris, France
2 shared publications Alisa Burova
Université de Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM UMR1266, « Genetic vulnerability to addictive and psychiatric disorders » team, Paris, France
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16
Fragmentomics features of cell free DNA in eating disorders
Eating disorders are lacking reliable biomarkers despite their severe psychiatric and medical burden. In this study, we examined plasma cell-free DNA (cfDNA) from patients with the restrictive (ANR), or binge-purge (ANBP) subtypes of anorexia nervosa, as well as from those with bulimia nervosa (BN), and controls, using the BIABooster electrophoresis method and shallow whole-genome sequencing to characterize cfDNA fragmentomics. While absolute cfDNA concentrations did not differ between groups, patients exhibited consistent qualitative alterations. Patients with BN showed increased cfDNA at the first nucleosomal peak, while all patient groups displayed shifts towards shorter fragments in the second and third nucleosomal peaks. End-motif analysis revealed higher motif diversity and trinucleotide sequence motifs TNN-type enrichment in ANR, together with a lower ratio of trinucleotide sequence motifs CGN to NCG, which has been correlated with hypomethylation. Multivariate analyses demonstrated that ANBP exhibits a distinct molecular profile that is not explained by combined effects of anorexia and bulimia. These findings suggest that cfDNA in eating disorders carries biologically meaningful signatures related to chromatin organization, nuclease activity, and methylation. This supports the potential of cfDNA as a minimally invasive biomarker for the clinical management of eating disorders.
- 12 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16
Open AccessFragmentomics features of cell free DNA in eating disorders
Eating disorders are lacking reliable biomarkers despite their severe psychiatric and medical burden. In this study, we examined plasma cell-free DNA (cfDNA) from patients with the restrictive (ANR), or binge-purge (ANBP) subtypes of anorexia nervosa, as well as from those with bulimia nervosa (BN), and controls, using the BIABooster electrophoresis method and shallow whole-genome sequencing to characterize cfDNA fragmentomics. While absolute cfDNA concentrations did not differ between groups, patients exhibited consistent qualitative alterations. Patients with BN showed increased cfDNA at the first nucleosomal peak, while all patient groups displayed shifts towards shorter fragments in the second and third nucleosomal peaks. End-motif analysis revealed higher motif diversity and trinucleotide sequence motifs TNN-type enrichment in ANR, together with a lower ratio of trinucleotide sequence motifs CGN to NCG, which has been correlated with hypomethylation. Multivariate analyses demonstrated that ANBP exhibits a distinct molecular profile that is not explained by combined effects of anorexia and bulimia. These findings suggest that cfDNA in eating disorders carries biologically meaningful signatures related to chromatin organization, nuclease activity, and methylation. This supports the potential of cfDNA as a minimally invasive biomarker for the clinical management of eating disorders.
- Open Access
- 5 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
The role of LEAP2 on cognitive impulsivity after refeeding: evidence from a preclinical study in female mice and from patients with anorexia nervosa
Recents findings suggest that the ghrelin/LEAP2 (Liver Expressed Antimicrobial Peptide 2) ratio impacts the dynamics of reward sensitivity, and that LEAP2 may serve as a biomarker of remission in patients with anorexia nervosa (AN). We hypothesized that the ghrelin/LEAP2 ratio influences impulsive food choices following chronic food restriction and refeeding. Impulse control and plasma ghrelin and LEAP2 concentrations were evaluated in a longitudinal study of 30 female patients with AN after weight restoration and 6-months following discharge to evaluate their weight gain status. Cognitive impulsivity was also assessed in young C57Bl6/J female mice at baseline, after 15 days of 50% quantitative food restriction and after 10 days of refeeding. We collected blood for ghrelin and LEAP2 measurement and brain structures involved in metabolic response, reward and cognitive control. The ghrelin/LEAP2 ratio was negatively correlated with impulse control in patients after weight restoration, but only in those who maintained stable weight gain after discharge. In mice, food restriction increased cognitive impulsivity and refeeding only partially restored this phenotype compared to control conditions. Cognitive impulsivity was also positively correlated with plasma LEAP2 levels but not with the expression of the key hypothalamic neuropeptides or mesocorticolimbic dopamine DRD1/DRD2 receptors. Our results suggest that the interaction between LEAP2 and cognitive impulsivity is affected by changes in nutritional status in patients and female mice. Metabolic and cognitive consequences of food restriction may influence how food choices are modified in patients with AN and may be associated with a greater likelihood of achieving stable weight gain.
- 5 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1)
Open AccessThe role of LEAP2 on cognitive impulsivity after refeeding: evidence from a preclinical study in female mice and from patients with anorexia nervosa
Recents findings suggest that the ghrelin/LEAP2 (Liver Expressed Antimicrobial Peptide 2) ratio impacts the dynamics of reward sensitivity, and that LEAP2 may serve as a biomarker of remission in patients with anorexia nervosa (AN). We hypothesized that the ghrelin/LEAP2 ratio influences impulsive food choices following chronic food restriction and refeeding. Impulse control and plasma ghrelin and LEAP2 concentrations were evaluated in a longitudinal study of 30 female patients with AN after weight restoration and 6-months following discharge to evaluate their weight gain status. Cognitive impulsivity was also assessed in young C57Bl6/J female mice at baseline, after 15 days of 50% quantitative food restriction and after 10 days of refeeding. We collected blood for ghrelin and LEAP2 measurement and brain structures involved in metabolic response, reward and cognitive control. The ghrelin/LEAP2 ratio was negatively correlated with impulse control in patients after weight restoration, but only in those who maintained stable weight gain after discharge. In mice, food restriction increased cognitive impulsivity and refeeding only partially restored this phenotype compared to control conditions. Cognitive impulsivity was also positively correlated with plasma LEAP2 levels but not with the expression of the key hypothalamic neuropeptides or mesocorticolimbic dopamine DRD1/DRD2 receptors. Our results suggest that the interaction between LEAP2 and cognitive impulsivity is affected by changes in nutritional status in patients and female mice. Metabolic and cognitive consequences of food restriction may influence how food choices are modified in patients with AN and may be associated with a greater likelihood of achieving stable weight gain.
- Open Access
- 17 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-10
Unraveling the brain expression of bdnf in a mouse model of anorexia nervosa
Anorexia nervosa (AN) is a complex psychiatric disorder characterized by severe caloric restriction and distorted body image, leading to significant psychological and physiological complications. Brain-derived neurotrophic factor (BDNF) plays a critical role in cognitive function and metabolic regulation. A mutation in the BDNF gene is associated with anorexia nervosa. This study examines the effects of food restriction, refeeding and short-term refeeding on the expression of Bdnf and its receptor (tropomyosin receptor kinase B TrkB/Ntrk2) in key brain regions involved in reward and cognitive function. We assessed BDNF mRNA levels in the dorsal striatum (DS), nucleus accumbens, ventral tegmental area, and prefrontal cortex (PFC) of AN-like mice subjected to different feeding regimes combined with or without physical activity. Cognitive flexibility was assessed using the Y-maze test. Whole RNA sequencing was also performed to analyse gene expression changes. Food restriction induced a transient decrease in cognitive flexibility and significantly decreased Bdnf expression in the DS and PFC. Progressive refeeding restored Bdnf in the DS but not the PFC. Short refeeding restored Bdnf levels to baseline. TrkB expression is increased by restriction only in the PFC. The presence of a running wheel cancelled these effects, suggesting an interaction between physical activity and diet. Pathway analysis of dysregulated genes revealed enrichment in immune regulation and cell-cell communication pathways. These findings highlight the complex relationship between diet, exercise, and brain function in AN-like mouse model and suggest avenues for further research into the clinical relevance of BDNF and TrkB as biomarkers of eating disorders.
- 17 October 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-10
Open AccessUnraveling the brain expression of bdnf in a mouse model of anorexia nervosa
Anorexia nervosa (AN) is a complex psychiatric disorder characterized by severe caloric restriction and distorted body image, leading to significant psychological and physiological complications. Brain-derived neurotrophic factor (BDNF) plays a critical role in cognitive function and metabolic regulation. A mutation in the BDNF gene is associated with anorexia nervosa. This study examines the effects of food restriction, refeeding and short-term refeeding on the expression of Bdnf and its receptor (tropomyosin receptor kinase B TrkB/Ntrk2) in key brain regions involved in reward and cognitive function. We assessed BDNF mRNA levels in the dorsal striatum (DS), nucleus accumbens, ventral tegmental area, and prefrontal cortex (PFC) of AN-like mice subjected to different feeding regimes combined with or without physical activity. Cognitive flexibility was assessed using the Y-maze test. Whole RNA sequencing was also performed to analyse gene expression changes. Food restriction induced a transient decrease in cognitive flexibility and significantly decreased Bdnf expression in the DS and PFC. Progressive refeeding restored Bdnf in the DS but not the PFC. Short refeeding restored Bdnf levels to baseline. TrkB expression is increased by restriction only in the PFC. The presence of a running wheel cancelled these effects, suggesting an interaction between physical activity and diet. Pathway analysis of dysregulated genes revealed enrichment in immune regulation and cell-cell communication pathways. These findings highlight the complex relationship between diet, exercise, and brain function in AN-like mouse model and suggest avenues for further research into the clinical relevance of BDNF and TrkB as biomarkers of eating disorders.